Search

miR‐29 family is one of the small noncoding RNAs and has a very important role in many physiologic and pathologic functions through regulating the target genes that play roles in various bioprocesses such as proliferation, survival, apoptosis, and angiogenesis. Thus, we aim to survey the potential of the miR‐29 family in normal model and development and progression of malignancy in this study. In addition, the potential role of miR‐29 family has been studied as the clinical marker for the diagnosis and prognosis of many cancers as the potential targets to treat cancer. Moreover, it was stated in summary that the herbal compounds can regulate miR‐29 family in cancers. Therefore, regulating the expression of the miR‐29 family in a variety of cancers can be a new strategy to obtain better results from cancerous patients' treatment in the future. [ABSTRACT FROM AUTHOR]

• Immune checkpoints are the regulators of the immune system as well as several cancers, including blood malignancies. • Immune checkpoints are considered as clinical markers in blood malignancies and also as potential targets for the treatment of this cancer type. • The regulation of immune checkpoints in blood cancers can be employed as a novel strategy to obtain effective results in blood cancers treatment. Immune checkpoints are the regulators of the immune system, which include stimulatory and inhibitory receptors. They play substantial roles in the maintenance of immune system homeostasis and the prevention of autoimmunity and cancer. In the current review, immune checkpoints roles are surveyed in the initiation, progression, and treatment of blood malignancies. The significant roles of immune checkpoints are discussed as clinical markers in the diagnosis and prognosis of a plethora of blood malignancies and also as potential targets for the treatment of these malignancies. It could be concluded that the regulation of immune checkpoints in various blood cancers can be employed as a novel strategy to obtain effective results in leukemia treatment and introduce immune checkpoint inhibitors as sufficient weapons against blood cancers in the future. [ABSTRACT FROM AUTHOR]